Trial Profile

A Phase 1 clinical study of XTX201

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 09 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Mar 2020 New trial record
02 Mar 2020 According to a Xilio Therapeutics media release, Akrevia Therapeutics has changed its name to Xilio Therapeutics.
02 Mar 2020 According to an Akrevia Therapeutics, Xilio Therapeutics media release, the company announced the closing of Series B financing. Proceeds from the financing will be used to progress XTX201 (tumor-selective IL-2) through Investigational New Drug (IND) enabling studies and into Phase 1 clinical trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com